This inventor holds 33 USPTO granted patents, primarily in Serotonin Receptor Research. Top assignees: Synaptic Pharmaceutical Corporation, Neurogenetic Corporation, H. Lundbeck A/s. Active years: 1991-2005.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Princeton, NJ (US) (1995 - 2000)
- Mahwah, NJ (US) (1991 - 2002)
- Pennington, NJ (US) (1998 - 2003)
- Kinnelon, NJ (US) (1995 - 2005)
Company Filing History:
29 out of 126 
2 out of 2 
1 out of 513 
Years Active: 1991-2005
Areas of Expertise:
Title: **The Innovative Contributions of Paul R. Hartig**
Introduction
Paul R. Hartig, located in Mahwah, NJ, is a prominent inventor with 33 patented innovations to his name. His work primarily revolves around advancements in biochemistry, specifically focusing on receptors and therapeutic compounds, making significant contributions to medical science.
Latest Patents
Hartig's recent inventions showcase his expertise in the field. One notable patent is titled "DNA encoding a human dopamine D1 receptor and uses thereof." This invention provides isolated nucleic acid molecules encoding the human dopamine D1 receptor, isolated proteins, vectors that comprise these nucleic acids, mammalian cells containing such vectors, and antibodies directed at the receptor. It also includes nucleic acid probes for detecting encoding and antisense oligonucleotides that are complementary to sequences of this nucleic acid. Furthermore, it outlines pharmaceutical compounds related to the human dopamine D1 receptor and explores methods for determining ligand binding, detecting expression, drug screening, and treatment involving this receptor.
Another significant patent is for the "Use of α1C specific compounds to treat benign prostatic hyperplasia." This invention details a method for treating benign prostatic hyperplasia by administering a therapeutically effective compound that binds selectively to human α adrenergic receptors with a substantially greater binding affinity than that with which the compound binds to other related receptors.
Career Highlights
Throughout his career, Paul Hartig has been associated with notable companies, including Synaptic Pharmaceutical Corporation and Neurogenetic Corporation. His innovations have paved the way for advancements in therapeutic strategies for various medical conditions.
Collaborations
Hartig has collaborated with esteemed colleagues in the field, including Theresa A. Branchek and Richard L. Weinshank. These collaborations have undoubtedly enhanced the innovation landscape in biopharmaceutical research.
Conclusion
Paul R. Hartig is an influential figure in the realm of biochemistry, with a strong portfolio of patents that have the potential to impact medical treatment and drug development significantly. His inventive contributions continue to drive progress and innovation in understanding human receptors and developing therapeutic applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile